We are live on ! Find out more
ENTL

Entellus Medical, Inc. Common Stock
ENTL

Delisted

ENTL was delisted on the 27th of February, 2018.

Back to rankings

0 hedge funds and large institutions have $0 invested in Entellus Medical, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 82 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 83 → 0 (-83)

100% less funds holding in top 10

Funds holding in top 10: 6 → 0 (-6)

100% less capital invested

Capital invested by funds: $441M → $0 (-$441M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 82

Holders
–
Holders Change
-83
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
82
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
EWM
Essex Woodlands Management
Texas
-$77.6M
2
SHI
SV Health Investors
Massachusetts
-$72.1M
3
KKRC
Kohlberg Kravis Roberts & Co
New York
-$34.3M
4
SGCM
Sand Grove Capital Management
United Kingdom
-$33.6M
5
ACH
ArrowMark Colorado Holdings
Colorado
-$24.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
GCL
26
Glazer Capital LLC
New York
– -$2.42M -99,000 Closed
GH
27
GAM Holding
Switzerland
– -$1.98M -81,315 Closed
William Blair & Company
28
William Blair & Company
Illinois
– -$1.84M -75,535 Closed
PAMP
29
Polar Asset Management Partners
Ontario, Canada
– -$1.83M -75,003 Closed
HA
30
Havens Advisors
New York
– -$1.68M -69,028 Closed
Ameriprise
31
Ameriprise
Minnesota
– -$1.68M -69,000 Closed
WA
32
Wasatch Advisors
Utah
– -$1.6M -65,482 Closed
PPA
33
Parametric Portfolio Associates
Washington
– -$1.48M -60,769 Closed
CCMW
34
Cypress Capital Management (Wyoming)
Wyoming
– -$1.45M -59,490 Closed
GLAM
35
Gardner Lewis Asset Management
Pennsylvania
– -$1.27M -52,000 Closed
Goldman Sachs
36
Goldman Sachs
New York
– -$1.26M -51,831 Closed
O
37
OppenheimerFunds
New York
– -$1.24M -50,661 Closed
Barclays
38
Barclays
United Kingdom
– -$1.22M -49,787 Closed
Charles Schwab
39
Charles Schwab
California
– -$1.1M -45,129 Closed
FIM
40
Freedom Investment Management
Connecticut
– -$1.09M -44,769 Closed
GCIA
41
Gabelli & Co Investment Advisers
New York
– -$1.05M -42,901 Closed
Bank of New York Mellon
42
Bank of New York Mellon
New York
– -$1.01M -41,484 Closed
GI
43
GAMCO Investors
Connecticut
– -$902K -37,000 Closed
TCIM
44
TIAA CREF Investment Management
New York
– -$774K -31,732 Closed
GPCM
45
Granite Point Capital Management
Massachusetts
– -$715K -29,300 Closed
Deutsche Bank
46
Deutsche Bank
Germany
– -$671K -27,587 Closed
KAM
47
Kassirer Asset Management
Ontario, Canada
– -$610K -25,000 Closed
JP Morgan Chase
48
JP Morgan Chase
New York
– -$551K -22,572 Closed
TA
49
Teachers Advisors
New York
– -$533K -21,836 Closed
Wells Fargo
50
Wells Fargo
California
– -$494K -20,257 Closed
1
2
3 4

ENTL Hedge Fund Activity: Q1 2018 in Review

0 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Entellus Medical, Inc. Common Stock (ENTL) for Q1 2018, worth a combined $0 — down 100% from $441M a quarter earlier.

Sellers outnumbered buyers: 82 funds closed out of ENTL and 0 opened new positions — a net loss of 82 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Essex Woodlands Management, exiting entirely with an estimated $77.6M sold.

  • 0 institutional investors held Entellus Medical, Inc. Common Stock (ENTL) as of Q1 2018, down from 83 in Q4 2017.
  • Funds reported $0 of Entellus Medical, Inc. Common Stock stock for Q1 2018, down 100% quarter-over-quarter.
  • 0 funds opened new Entellus Medical, Inc. Common Stock positions in Q1 2018 and 82 closed out, a net change of -82 holders.
  • The largest Entellus Medical, Inc. Common Stock seller in Q1 2018 was Essex Woodlands Management, an estimated $77.6M sold.

Based on aggregated 13F filings for Q1 2018.